GEVA : Summary for Synageva BioPharma Corp. - Yahoo Finance

U.S. Markets closed

Synageva BioPharma Corp. (GEVA)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
238.600.00 (0.00%)
At close: 3:59PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close238.60
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes8 days ago

    Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs

    Everytime Donald Trump tweets about drug prices, biotech stocks take it on the chin. Bruce Pile believes these episodes are giving informed investors good entry points for some of the best names in biotech.

  • Reuters2 years ago

    Alexion gets EU approval for drug acquired in Synageva deal

    Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration. "This is sort of a momentous year for us," Alexion Chief Executive David Hallal said in an interview.

  • GuruFocus.com2 years ago

    Columbia Wanger Sells 22 Stakes in Second Quarter

    Chicago-based Columbia Wanger (Trades, Portfolio) serves mostly investment companies, managing mutual funds for its clients.